Digital
28th -1st July 2021

4th Annual Next Gen Immuno-Oncology Virtual Congress-US Edition (Time Zone - EST)

Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress-US Edition to be held on 28th-1st July 2021 would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.

This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

WHAT TO EXPECT

Key Highlights

  • Updates in development of ADC’s and Bispecific Ab’s
  • Immune Checkpoint Inhibitors and Combinations
  • Biomarkers and Cancer Vaccines
  • CAR-T cell therapy, T-Cell Therapy
  • Tumor microenvironment
  • Oncolytic Viruses
  • Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)

Who Should Attend?

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on

  • Monoclonal and Bispecific Antibodies
  • Cell Therapy
  • Immune Checkpoint Inhibitors

Why Attend?

  • Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
  • Find out new case studies of immune-oncology projects in development
  • Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
  • Explore the latest platforms and technologies on the market for development
  • Discuss the best tool for your research in immune-oncology
  • Share your work and achievements with your industry peers in the Poster Sessions 

CONFERENCE AGENDA
CELLULAR THERAPY, PERSONALIZED IMMUNOTHERAPY, VACCINES AND ONCOLYTIC VIRAL THERAPY
IMMUNE CHECKPOINT INHIBITORS & COMBINATION STRATEGIES
CONFERENCE SPEAKERS
Speakers
Victor Levitsky
Victor Levitsky
Chief Scientific Officer, Targovax
De Yang
De Yang
Staff Scientist, NIH, National Cancer Institute, Center for Cancer Research
Lindy Durrant
Lindy Durrant
Professor, Cancer Immunotherapy, University of Nottingham, UK
Helena Kiefel
Helena Kiefel
Program Leader, Immuno-Oncology, Second Genome
Mark Exley
Mark Exley
Chief Scientific Officer, ImVax
Laura Codarri Deak
Laura Codarri Deak
Principal Scientist, Team Leader, Cancer Immunotherapy, Roche
Héctor Pérez Montoyo
Héctor Pérez Montoyo
Director, Biological Research, Ability Pharma
Steven Lynum
Steven Lynum
Executive Director Global Business Development, PHC Corporation
SPONSORS
Platinium
example-image

International Drug Development Institute

Gold
example-image

BIOCYTOGEN

example-image

Applied BioMath

Sponsors & Exhibitors
example-image

Larvol

example-image

PHC Group

example-image

Proteome Sciences

example-image

Agilent

example-image

BerGenBio

example-image

evorion biotechnologies GmbH

example-image

Imaging Endpoints

example-image

TransCure bioServices

Speaking Partner
example-image

Ultivue

example-image

Kiromic Biopharma

Primary Partner
example-image

Predicine

example-image

Personalis

PARTNERS
Supporting Association
Irish Stem Cell Foundation

Irish Stem Cell Foundation

Media Partners
example-image

PharmaVOICE

example-image

PharmaTutor

example-image

Pharma Journalist

example-image

Pharma China

example-image

PharmaShots

PAST EVENT GALLERY